Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

IMFINZI Study in Patients With Extensive Stage Small Cell Lung CancerCompleted
NCT04854590N/AUpdated Jul 24, 2024
Sponsor: AstraZeneca
Carcinoma, Small Cell
Japan
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous MelanomaWithdrawn
NCT02535078Phase 1, Phase 2Updated Jul 24, 2024
Sponsor: Immunocore Ltd
Malignant Melanoma
United States
Southeast Netherlands Advanced Metastatic Breast Cancer RegistryRecruiting
NCT03577197N/AUpdated Jul 23, 2024
Sponsor: Academisch Ziekenhuis Maastricht
Advanced Breast Cancer · Metastatic Breast Cancer
Netherlands
A Study to Compare Severe Asthma Patients Who Start Biologics and Who do Not Start (PROSPECT)Completed
NCT04808518N/AUpdated Jul 23, 2024
Sponsor: AstraZeneca
Asthma
Japan
A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC PatientsCompleted
NCT03485326N/AUpdated Jul 23, 2024
Sponsor: AstraZeneca
Non-small Cell Lung Cancer
China
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast CancerRecruiting
NCT06508216Phase 1, Phase 2Updated Jul 22, 2024
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Breast Cancer
France
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy SubjectsCompleted
NCT05384262Phase 1Updated Jul 19, 2024
Sponsor: AstraZeneca
Dyslipidemia
United States, United Kingdom
Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 DiabetesCompleted
NCT04556760Phase 2Updated Jul 18, 2024
Sponsor: AstraZeneca
Diabetes Mellitus, Type 2
Germany
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy VolunteersCompleted
NCT04076540Phase 1Updated Jul 17, 2024
Sponsor: AstraZeneca
Smoking Cessation
United States
PREP (Pre-Exposure Prophylaxis) of COVID-19Completed
NCT05461378N/AUpdated Jul 15, 2024
Sponsor: Ghady Haidar
Immuno-Deficiency · COVID-19
United States
Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI TherapyCompleted
NCT04207775N/AUpdated Jul 12, 2024
Sponsor: AstraZeneca
Locally Advanced or Metastatic NSCLC
China
Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast CancerCompleted
NCT04857619N/AUpdated Jul 11, 2024
Sponsor: AstraZeneca
Metastatic Breast Cancer
Australia, Brazil, Hong Kong, Singapore, South Korea +1 more
A Phase 2b Diabetic Kidney Disease StudyCompleted
NCT04170543Phase 2Updated Jul 10, 2024
Sponsor: AstraZeneca
Diabetic Kidney Disease
United States, Argentina, Canada, Chile, Japan +2 more
Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTCActive Not Recruiting
NCT06490107Phase 2Updated Jul 8, 2024
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Biliary Tract Cancer
China
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaUnknown
NCT03959293Phase 2Updated Jul 8, 2024
Sponsor: Federation Francophone de Cancerologie Digestive
Gastric Adenocarcinoma · Gastric Cancer
France
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR MutationsTerminated
NCT02954523Phase 1, Phase 2Updated Jul 5, 2024
Sponsor: Chul Kim
EGFR Gene Mutation · Nonsmall Cell Lung Cancer
United States
A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy ParticipantsCompleted
NCT06357520Phase 1Updated Jul 3, 2024
Sponsor: AstraZeneca
Healthy Participants
United States
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial CancerCompleted
NCT03557918Phase 2Updated Jul 3, 2024
Sponsor: Matthew Galsky
Urothelial Carcinoma
United States
Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral CavityUnknown
NCT03784066Phase 1, Phase 2Updated Jul 3, 2024
Sponsor: Universitaire Ziekenhuizen KU Leuven
Oral Cavity Squamous Cell Carcinoma
Belgium
Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.Completed
NCT03833141N/AUpdated Jul 1, 2024
Sponsor: AstraZeneca
Severe Eosinophilic Asthma
Canada
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)Terminated
NCT04908956Phase 2Updated Jun 28, 2024
Sponsor: ETOP IBCSG Partners Foundation
NSCLC Stage IV · EGFR Gene Mutation
Italy, Netherlands, Poland, Singapore, South Korea +3 more
An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in JapanCompleted
NCT06156982N/AUpdated Jun 26, 2024
Sponsor: AstraZeneca
COVID-19
Japan
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.Completed
NCT04642469Phase 3Updated Jun 25, 2024
Sponsor: AstraZeneca
Carcinoma, Non- Small Cell Lung
United States, Argentina, Australia, Belgium, Brazil +20 more
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years OldCompleted
NCT03199053Phase 3Updated Jun 21, 2024
Sponsor: AstraZeneca
Diabetes Mellitus, Type 2
United States, Argentina, Australia, Brazil, Canada +18 more
A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833Completed
NCT05364255Phase 1Updated Jun 21, 2024
Sponsor: AstraZeneca
ER-positive, HER2-negative Breast Cancer
United Kingdom

Previous page Next page